Index,NCTId,Condition,Change,Reference,Variable,Timepoint,Endpoint Art
0,NCT04984707,Androgenetic Alopecia,Incidence Of Treatment-Emergent Adverse Events (Teae),Not Mentioned,Assessments,3 Days,Primary Endpoint
1,NCT04984707,Androgenetic Alopecia,Incidence Of Treatment-Emergent Adverse Events (Teae),Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
2,NCT04984707,Androgenetic Alopecia,Incidence Of Treatment-Emergent Adverse Events (Teae),Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
3,NCT04984707,Androgenetic Alopecia,Incidence Of Treatment-Emergent Adverse Events (Teae),Not Mentioned,Tests,3 Days,Primary Endpoint
4,NCT04984707,Androgenetic Alopecia,Incidence Of Study Drug Related Teaes,Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
5,NCT04984707,Androgenetic Alopecia,Auc From Time 0,Not Mentioned,"Total Exposure(Aucinf), Extrapolated To Infinite Time",48 Hours,Secondary Endpoint
6,NCT04984707,Androgenetic Alopecia,-Zero Concentration(Auclast),Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
7,NCT04984707,Androgenetic Alopecia,Maximum Observed Concentration (Cmax),Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
8,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Time At Which Cmax Was First Observed(Tmax),48 Hours,Secondary Endpoint
9,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Half Life（T½）,48 Hours,Secondary Endpoint
10,NCT04984707,Androgenetic Alopecia,Dose/Aucinf(Cl/F),Not Mentioned,Apparent Total Systemic Clearance,48 Hours,Secondary Endpoint
11,NCT04984707,Androgenetic Alopecia,Distribution(Vd/F),Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
12,NCT04984707,Androgenetic Alopecia,Elimination Rate Constant（Kel）,Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
13,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At Baseline.,Primary Endpoint
14,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,Immediately After Intervention.,Primary Endpoint
15,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 4 Weeks After Intervention.,Primary Endpoint
16,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 12 Weeks After Intervention.,Primary Endpoint
17,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 24 Weeks After Intervention.,Primary Endpoint
18,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At Baseline.,Primary Endpoint
19,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,Immediately After Intervention.,Primary Endpoint
20,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 4 Weeks After Intervention.,Primary Endpoint
21,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 12 Weeks After Intervention.,Primary Endpoint
22,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 24 Weeks After Intervention.,Primary Endpoint
23,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At Baseline.,Primary Endpoint
24,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,Immediately After Intervention.,Primary Endpoint
25,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 4 Weeks After Intervention.,Primary Endpoint
26,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 12 Weeks After Intervention.,Primary Endpoint
27,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 24 Weeks After Intervention.,Primary Endpoint
28,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At Baseline.,Primary Endpoint
29,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,Immediately After Intervention.,Primary Endpoint
30,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 4 Weeks After Intervention.,Primary Endpoint
31,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 12 Weeks After Intervention.,Primary Endpoint
32,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 24 Weeks After Intervention.,Primary Endpoint
33,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At Baseline.,Primary Endpoint
34,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,Immediately After Intervention.,Primary Endpoint
35,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 4 Weeks After Intervention.,Primary Endpoint
36,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 12 Weeks After Intervention.,Primary Endpoint
37,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 24 Weeks After Intervention.,Primary Endpoint
38,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
39,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
40,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
41,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
42,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
43,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",-Senior Fitness Test (Sft),Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
44,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",-Senior Fitness Test (Sft),Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
45,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",-Senior Fitness Test (Sft),Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
46,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",-Senior Fitness Test (Sft),Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
47,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",-Senior Fitness Test (Sft),Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
48,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Test (Ust),Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
49,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Test (Ust),Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
50,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Test (Ust),Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
51,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Test (Ust),Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
52,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Test (Ust),Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
53,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Psychosocial Factors-Global,Not Mentioned,Being Scale (Gwbs),At Baseline.,Secondary Endpoint
54,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Psychosocial Factors-Global,Not Mentioned,Being Scale (Gwbs),Immediately After Intervention.,Secondary Endpoint
55,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Psychosocial Factors-Global,Not Mentioned,Being Scale (Gwbs),At 4 Weeks After Intervention.,Secondary Endpoint
56,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Psychosocial Factors-Global,Not Mentioned,Being Scale (Gwbs),At 12 Weeks After Intervention.,Secondary Endpoint
57,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Psychosocial Factors-Global,Not Mentioned,Being Scale (Gwbs),At 24 Weeks After Intervention.,Secondary Endpoint
58,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Psychosocial Factors-Interpersonal Relationship Scale (Irs),Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
59,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Psychosocial Factors-Interpersonal Relationship Scale (Irs),Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
60,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Psychosocial Factors-Interpersonal Relationship Scale (Irs),Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
61,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Psychosocial Factors-Interpersonal Relationship Scale (Irs),Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
62,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Psychosocial Factors-Interpersonal Relationship Scale (Irs),Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
63,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Sf),Not Mentioned,Scale-Short,At Baseline.,Secondary Endpoint
64,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Sf),Not Mentioned,Scale-Short,Immediately After Intervention.,Secondary Endpoint
65,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Sf),Not Mentioned,Scale-Short,At 4 Weeks After Intervention.,Secondary Endpoint
66,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Sf),Not Mentioned,Scale-Short,At 12 Weeks After Intervention.,Secondary Endpoint
67,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Sf),Not Mentioned,Scale-Short,At 24 Weeks After Intervention.,Secondary Endpoint
68,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Quality Of Life-Eq5D-Utility,Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
69,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Quality Of Life-Eq5D-Utility,Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
70,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Quality Of Life-Eq5D-Utility,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
71,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Quality Of Life-Eq5D-Utility,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
72,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Quality Of Life-Eq5D-Utility,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
73,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Quality Of Life-Eq5D-Visual Analogue Scale,Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
74,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Quality Of Life-Eq5D-Visual Analogue Scale,Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
75,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Quality Of Life-Eq5D-Visual Analogue Scale,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
76,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Quality Of Life-Eq5D-Visual Analogue Scale,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
77,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Quality Of Life-Eq5D-Visual Analogue Scale,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
78,NCT04984564,Educational Problems,Training On Virtual,Not Mentioned,Simulator Based Learning.,Survey Was Conducted From August To July 2020. Subjects Had Two Month Period To Respond.,Primary Endpoint
79,NCT04984564,Educational Problems,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
80,NCT04984135,"Coronary Stenosis, Drug-Coated Balloon",In-Segment Late Lumen Loss,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
81,NCT04984135,"Coronary Stenosis, Drug-Coated Balloon",Not Mentioned,Not Mentioned,Target Lesion Failure,6 Months,Secondary Endpoint
82,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Mmp8,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
83,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs","Il1, Il6,Il8,Il17",Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
84,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Tnf Alfa,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
85,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Rank-L,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
86,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Opg,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
87,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Cal,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
88,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
89,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Gi,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
90,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
91,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Fmbs,Baseline - 1 Week,Secondary Endpoint
92,NCT04983719,"Atypical, Myoma",Not Mentioned,"Video, Evaluation","Video, Evaluation",Day 1,Primary Endpoint
93,NCT04983719,"Atypical, Myoma",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
94,NCT04983641,Orthopedic Disorder,Scheduled Clinic Visit,Patient Portal,Not Mentioned,1 Week,Primary Endpoint
95,NCT04983641,Orthopedic Disorder,Scheduled Clinic Visit,"At-Visit Promis, Patient Portal","At-Visit Promis, Patient Portal",1 Week,Primary Endpoint
96,NCT04983641,Orthopedic Disorder,Scheduled Clinic Visit,"At-Visit) Promis, Patient Portal, Overall (Pre-Visit","At-Visit) Promis, Patient Portal, Overall (Pre-Visit",1 Week,Primary Endpoint
97,NCT04983641,Orthopedic Disorder,Not Mentioned,Not Mentioned,Time To Pre-Visit Promis,1 Week,Secondary Endpoint
98,NCT04983641,Orthopedic Disorder,Not Mentioned,Patient Demographics,Not Mentioned,1 Week,Secondary Endpoint
99,NCT04983524,"Post-Operative Pain, Chronic, Necrotic Pulp",Not Mentioned,Not Mentioned,Not Mentioned,One Week. Line Of 10 Points,Primary Endpoint
100,NCT04983524,"Post-Operative Pain, Chronic, Necrotic Pulp",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
101,NCT04983459,"Prostatic Neoplasms, Recurrence",Detection Rate Per Patient,"Detection, Biochemical Recurrence., Pet-Psma","Detection, Biochemical Recurrence., Pet-Psma",12 Months,Primary Endpoint
102,NCT04983459,"Prostatic Neoplasms, Recurrence",Biochemical Recurrence,"Detection, Psma-Pet","Detection, Psma-Pet",12 Months,Secondary Endpoint
103,NCT04983381,"Pelvic Pain, Pelvic Floor; Relaxation",Not Mentioned,Not Mentioned,Pelvic Examination,6 Months,Primary Endpoint
104,NCT04983381,"Pelvic Pain, Pelvic Floor; Relaxation",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
105,NCT04983212,Peri-Implantitis,Not Mentioned,Not Mentioned,Prevalence,01/01/2015 - 01/01/2020,Primary Endpoint
106,NCT04983212,Peri-Implantitis,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
107,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,"Microparticles Derived From Endothelial Cells, Circulating Endothelial Progenitor Cells Concentration","Data Collected After 4 Weeks, 8 Weeks And 12 Weeks.",Primary Endpoint
108,NCT04983160,Chronic Kidney Disease,Level Of Oxidative Stress,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
109,NCT04983160,Chronic Kidney Disease,Level Of Micro Inflammation,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
110,NCT04983160,Chronic Kidney Disease,Level Of Endothelial Dysfunction,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
111,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Blood Pressure,"Each Visit (0 Weeks, 4 Weeks, 8 Weeks And 12 Weeks) For 24 Hours",Secondary Endpoint
112,NCT04983160,Chronic Kidney Disease,Glomerular Filtration Ratio,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4 Weeks, 8 Weeks And 12 Weeks)",Secondary Endpoint
113,NCT04983160,Chronic Kidney Disease,Microalbuminuria / Proteinuria,Not Mentioned,Not Mentioned,"Daily, Using First Urine Of The Day As A Sample.",Secondary Endpoint
114,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Introductory Information,Up To 12 Weeks,Primary Endpoint
115,NCT04983147,Obesity,-Scale),Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
116,NCT04983147,Obesity,-Scale),Importance,Not Mentioned,Up To 12 Weeks,Primary Endpoint
117,NCT04983147,Obesity,-Scale),Scale,Not Mentioned,Up To 12 Weeks,Primary Endpoint
118,NCT04983147,Obesity,-Scale),Scale,Not Mentioned,Up To 12 Weeks,Primary Endpoint
119,NCT04983147,Obesity,-Scale),Scale,Not Mentioned,Up To 12 Weeks,Primary Endpoint
120,NCT04983147,Obesity,-Scale),Scale,Not Mentioned,Up To 12 Weeks,Primary Endpoint
121,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
122,NCT04983147,Obesity,Weighing Machine,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
123,NCT04983147,Obesity,Body Mass Index Calculation,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
124,NCT04983147,Obesity,Scale In Obesity ((Questionnaire-Scale),Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
125,NCT04983147,Obesity,-Scale),Importance,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
126,NCT04983147,Obesity,-Scale),Scale,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
127,NCT04983147,Obesity,-Scale),Scale,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
128,NCT04983147,Obesity,-Scale),Scale,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
129,NCT04983147,Obesity,-Scale),Scale,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
130,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
131,NCT04983147,Obesity,Weighing Machine,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
132,NCT04983147,Obesity,Body Mass Index Calculation,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
133,NCT04983056,Fournier Gangrene,Number Of Patients,Not Mentioned,Not Mentioned,Six Months,Primary Endpoint
134,NCT04983056,Fournier Gangrene,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
135,NCT04982978,Vaping Related Disorder,Not Mentioned,Not Mentioned,"Vaping Intention, Effect Of Threat Appraisal",6-Weeks,Primary Endpoint
136,NCT04982978,Vaping Related Disorder,Perceived Vulnerability,"Effect, Intention","Effect, Intention",6-Weeks,Secondary Endpoint
137,NCT04982978,Vaping Related Disorder,Perceived Severity,"Effect, Intention","Effect, Intention",6-Weeks,Secondary Endpoint
138,NCT04982874,Drug Use,Not Mentioned,Geometric Mean,Not Mentioned,1 Month,Primary Endpoint
139,NCT04982874,Drug Use,90% Confidence Intervals,Not Mentioned,Not Mentioned,1 Month,Primary Endpoint
140,NCT04982874,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,1 Month,Secondary Endpoint
141,NCT04982874,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,1 Month,Secondary Endpoint
142,NCT04982861,Drug Use,Not Mentioned,Geometric Mean,Not Mentioned,3 Months,Primary Endpoint
143,NCT04982861,Drug Use,90% Confidence Intervals,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
144,NCT04982861,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
145,NCT04982861,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
146,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Lungen - 6 (Kl-6),3 Months,Primary Endpoint
147,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
148,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
149,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
150,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
151,NCT04982809,Interstitial Lung Disease,% O2 Desaturation,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
152,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Visual Analog Scale(Vas),6 Weeks,Primary Endpoint
153,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Disability Scale (Npds),6 Weeks,Primary Endpoint
154,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Neck And Jaw Range Of Motion (Rom),Not Mentioned,Not Mentioned,6 Weeks,Primary Endpoint
155,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Quality Index (Puqi),Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
156,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Inventory (Bdi),Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
157,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",36 (Sf36),Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
158,NCT04982523,Post Traumatic Stress Disorder,Change Of Post-Traumatic Stress Symptoms,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Primary Endpoint
159,NCT04982523,Post Traumatic Stress Disorder,Change Of Depression,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
160,NCT04982523,Post Traumatic Stress Disorder,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
161,NCT04982523,Post Traumatic Stress Disorder,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
162,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Day 0,Not Mentioned,Reading Speed,Day 0,Primary Endpoint
163,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,Not Mentioned,Reading Speed M3,Month 3,Primary Endpoint
164,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Etdrs Chart,Not Mentioned,Not Mentioned,Day 0,Secondary Endpoint
165,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Visual Acuity,Not Mentioned,Not Mentioned,Month 3,Secondary Endpoint
166,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Maculare Thickness Day0,Not Mentioned,Not Mentioned,Day 0,Secondary Endpoint
167,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Maculare Thickness M3,Not Mentioned,Not Mentioned,Month 3,Secondary Endpoint
168,NCT04982341,Hypoxemic Respiratory Failure,Number Of Patients,Not Mentioned,Intubation,"Through Study Completion, An Average Of 28 Days",Primary Endpoint
169,NCT04982341,Hypoxemic Respiratory Failure,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
170,NCT04982263,Covid19,Not Mentioned,"Results Of Laboratory Test, Correlation, Disease Severity","Results Of Laboratory Test, Correlation, Disease Severity",Baseline Results Of Coagulation Profile And Baseline Disease Severity Assessment,Primary Endpoint
171,NCT04982263,Covid19,Not Mentioned,Not Mentioned,Coagulation Profile,Baseline Measurement Of Inflammatory Markers,Secondary Endpoint
172,NCT04982159,Invasive Fusariosis,Not Mentioned,Clinical Evolution,Not Mentioned,6 Weeks After Diagnosis,Primary Endpoint
173,NCT04982159,Invasive Fusariosis,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
174,NCT04982055,Critical Illness,Peak Anti-Xa Activity,Not Mentioned,Not Mentioned,Peak Anti-Xa Activity Obtained 4 Hours After Start Of Low Molecular Weight Heparin Administration,Primary Endpoint
175,NCT04982055,Critical Illness,Not Mentioned,Not Mentioned,Activity,Trough Anti-Xa Activity Measured 24 Hours After Start Of Low Molecular Weight Administration,Secondary Endpoint
176,NCT04982055,Critical Illness,Auc (0-24H,Not Mentioned,Not Mentioned,0-24 Hours,Secondary Endpoint
177,NCT04981652,"Dairy Products, Muscle Protein Synthesis, Aging, Physical Activity",Not Mentioned,Not Mentioned,Not Mentioned,"Assessed At Baseline (Day 0-3), Intervention Diet (4-7) And Intervention Diet + Activity (Day 8-10)",Primary Endpoint
178,NCT04981652,"Dairy Products, Muscle Protein Synthesis, Aging, Physical Activity",Not Mentioned,Not Mentioned,Not Mentioned,"Assessed At Baseline (Day 0-3), Intervention Diet (4-7) And Intervention Diet + Activity (Day 8-10)",Secondary Endpoint
179,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Treatment Emergent Adverse Events,28 Days,Primary Endpoint
180,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Concentration,24 Hours,Secondary Endpoint
181,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Time To Maximum Plasma Concentration,24 Hours,Secondary Endpoint
182,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,"Area Under The Curve, Concentration",72 Hours,Secondary Endpoint
183,NCT04981483,Placenta Accreta,Incidence Rate Of Conserving Woman'S Uterus,Not Mentioned,Not Mentioned,Intraoperative,Primary Endpoint
184,NCT04981483,Placenta Accreta,Number Of Units Of Packed,Not Mentioned,Blood Cells,Till 48 Hours Postpartum,Secondary Endpoint
185,NCT04981483,Placenta Accreta,Incidence Rate Of Cesarean Hysterectomy Needed,Not Mentioned,Not Mentioned,Intraoperative And 48 Hours Postpartum,Secondary Endpoint
186,NCT04981483,Placenta Accreta,Incidence Of Puerperal Sepsis,Not Mentioned,Not Mentioned,Till 6 Weeks Postpartum,Secondary Endpoint
187,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,During The Study,Primary Endpoint
188,NCT04981379,Covid19,Complete Resolution Of Symptoms,Not Mentioned,Not Mentioned,Fifth Day After Examination,Secondary Endpoint
189,NCT04981379,Covid19,Complete Resolution Of Symptoms,Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
190,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Negative Rt-Pcr Test,Tenth Day After Examination,Secondary Endpoint
191,NCT04981379,Covid19,"Determination Of Igm, Igg Levels",Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
192,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Negative Rt-Pcr Test,Thirtieth Day After Examination,Secondary Endpoint
193,NCT04981379,Covid19,"Determination Of Igm, Igg Antibodies",Not Mentioned,Not Mentioned,Thirtieth Day After Examination,Secondary Endpoint
194,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Pneumonia,During The Study,Secondary Endpoint
195,NCT04981379,Covid19,Oxygen Mask,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
196,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
197,NCT04981379,Covid19,Requirement Of Mechanical Ventilation,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
198,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
199,NCT04981379,Covid19,The Rate Of Discontinuation,Not Mentioned,Treatments,During The Study,Secondary Endpoint
200,NCT04981379,Covid19,Not Mentioned,Not Mentioned,"Time To Improvement Of Symptoms, Drugs",During The Study,Secondary Endpoint
201,NCT04981249,"Covid-19, Chronic Disease",Not Mentioned,Not Mentioned,Not Mentioned,From 27-February-2020 To 15-June-2020,Primary Endpoint
202,NCT04981249,"Covid-19, Chronic Disease",Covid-19 Mortality,Not Mentioned,Not Mentioned,From 27-February-2020 To 15-June-2020,Primary Endpoint
203,NCT04981249,"Covid-19, Chronic Disease",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
204,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,"Scale Scores, Changes","Baseline, 4 Week, 8 Week, 12 Week",Primary Endpoint
205,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Changes,"Baseline, 4 Week, 8 Week, 12 Week",Primary Endpoint
206,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,"Quality Index Scores, Changes","Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
207,NCT04981197,Heart Failure,Depression Scale Scores,Not Mentioned,Changes,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
208,NCT04981197,Heart Failure,Changes In Heart Rate Variability,Not Mentioned,Not Mentioned,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
209,NCT04981106,Exercise,Tampa Kinesiophobia Index,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 58.2; Control 54.1),Primary Endpoint
210,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Index,First Measurement Two Weeks After Surgery (Intervetion 89.3; Control 88.1),Primary Endpoint
211,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 21.6; Control 22.1),Primary Endpoint
212,NCT04981106,Exercise,Tampa Kinesiophobia Index,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 36.9; Control 42.9),Secondary Endpoint
213,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Index,Second Measurement Six Weeks After Surgery (Intervetion 29; Control 70.5),Secondary Endpoint
214,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 6.9; Control 13.2),Secondary Endpoint
215,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Not Mentioned,Not Mentioned,Not Mentioned,February 2005 And December 2020,Primary Endpoint
216,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Not Mentioned,Not Mentioned,Bladder Outlet Obstruction,February 2005 And December 2020,Primary Endpoint
217,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
218,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Bladder Oversensitivity,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
219,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Detrusor Overactivity,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
220,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
221,NCT04981015,Bladder Oversensitivity,Parameters,Correlation,Not Mentioned,July 2009 To December 2020,Primary Endpoint
222,NCT04981015,Bladder Oversensitivity,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
223,NCT04980989,"Breast Cancer, Early-Onset",Up Modality,Not Mentioned,Not Mentioned,At 12 Months During Follow-Up Of Early Breast Cancer,Primary Endpoint
224,NCT04980989,"Breast Cancer, Early-Onset",Quality Of Life During Follow-Up Modality,Not Mentioned,Not Mentioned,"At Baseline, 6 Months And 12 Months",Secondary Endpoint
225,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Patient Satisfaction,At 6 Months And 12 Months,Secondary Endpoint
226,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Not Mentioned,"At Baseline, 6 Months And 12 Months",Secondary Endpoint
227,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Not Mentioned,At 6 Months And 12 Months,Secondary Endpoint
228,NCT04980937,"Traumatic Injury, Peroneal Nerve Injury, Sport Injury",Successful Nerve Reconstruction,Not Mentioned,Not Mentioned,1 Year,Primary Endpoint
229,NCT04980937,"Traumatic Injury, Peroneal Nerve Injury, Sport Injury",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
230,NCT04980729,Pelvic Tumor,Rotation Center Before,"Template-Guided Group, Traditional Operation Group., Surgery","Template-Guided Group, Traditional Operation Group., Surgery","""Through Study Completion, An Average Of 2 Years""",Primary Endpoint
231,NCT04980729,Pelvic Tumor,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
232,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Not Mentioned,Not Mentioned,Cheeks Appearance,Immediately After The Evaluation,Primary Endpoint
233,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Thickness Evaluation,Not Mentioned,Orofacial Muscles,Immediately After The Evaluation,Secondary Endpoint
234,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Not Mentioned,Not Mentioned,Tongue,Immediately After The Evaluation,Secondary Endpoint
235,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Corpus Cavernosum Electromyography Amplitudes,Not Mentioned,Not Mentioned,1 Hour,Primary Endpoint
236,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Corpus Cavernosum Electromyography Relaxation Degree,Not Mentioned,Not Mentioned,1 Hour,Primary Endpoint
237,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
238,NCT04980274,Critically Ill Patients,Sofa Score After 48 Hours Of Icu Stay,Improvement,Not Mentioned,48 Hours,Primary Endpoint
239,NCT04980274,Critically Ill Patients,28 Day Mortality,Not Mentioned,Not Mentioned,28 Days,Secondary Endpoint
240,NCT04980274,Critically Ill Patients,Length Of Time Without Mechanical Ventilation,Not Mentioned,Not Mentioned,28 Days,Secondary Endpoint
241,NCT04980274,Critically Ill Patients,Length Of Time Without Vasopressor,Not Mentioned,Not Mentioned,28 Days,Secondary Endpoint
242,NCT04980209,Femoroacetabular Impingement,Vas Scale,Not Mentioned,Not Mentioned,1 Year After Operation,Primary Endpoint
243,NCT04980209,Femoroacetabular Impingement,Mhhs Scale,Not Mentioned,Not Mentioned,1 Year After Operation,Primary Endpoint
244,NCT04980209,Femoroacetabular Impingement,Hip Ct,Not Mentioned,Not Mentioned,1 Day After Operation,Primary Endpoint
245,NCT04980209,Femoroacetabular Impingement,Hip X-Ray,Not Mentioned,Not Mentioned,1 Day After Operation,Primary Endpoint
246,NCT04980209,Femoroacetabular Impingement,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
247,NCT04980196,Urogenital Prolapse,Urinary Tract Dysfunction.,Not Mentioned,Pelvic Organ Prolapse,3Months,Primary Endpoint
248,NCT04980196,Urogenital Prolapse,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
249,NCT04980131,Vertebral Fracture,Dosage Before,Not Mentioned,Time Before Reaching The Desired Position,Twenty Months,Primary Endpoint
250,NCT04980131,Vertebral Fracture,Vas Scores After Surgery,Not Mentioned,Not Mentioned,Twenty-Two Months,Primary Endpoint
251,NCT04980131,Vertebral Fracture,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
252,NCT04980118,"Breast Cancer, Body Weight Changes, Weight Loss, Nutrition Related Cancer",Physical Activity Program.,Not Mentioned,Cancer 9 Weight Control,Six Months,Primary Endpoint
253,NCT04980118,"Breast Cancer, Body Weight Changes, Weight Loss, Nutrition Related Cancer",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
254,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
255,NCT04980040,Type 2 Diabetes Mellitus,Reactions (Adrs),Not Mentioned,Not Mentioned,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
256,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Adverse Events,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
257,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
258,NCT04980040,Type 2 Diabetes Mellitus,Haemoglobin (Hba1C) Levels,Not Mentioned,Not Mentioned,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
259,NCT04980040,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Fasting Blood Glucose Levels,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
260,NCT04980040,Type 2 Diabetes Mellitus,7.00%,Not Mentioned,Not Mentioned,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
261,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Final Effectiveness Assessment,Up To Week 26,Secondary Endpoint
262,NCT04980014,Type 2 Diabetes Mellitus,Reactions (Sadrs),Not Mentioned,Not Mentioned,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
263,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,"Adverse Drug Reactions (Adrs) Not Mentioned, Unexpected Adverse Events (Aes)",First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
264,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Adrs,Week 13,Primary Endpoint
265,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Adrs,Week 26,Primary Endpoint
266,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Adrs,Week 39,Primary Endpoint
267,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Adrs,Week 52,Primary Endpoint
268,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Adrs,Week 153,Primary Endpoint
269,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
270,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Abnormal Laboratory Findings Reported As Aes,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
271,NCT04980014,Type 2 Diabetes Mellitus,Haemoglobin A1C (Hba1C) Levels,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
272,NCT04980014,Type 2 Diabetes Mellitus,Change,"Fasting Serum Glucose, Baseline","Fasting Serum Glucose, Baseline","Baseline, Weeks 13 And 26",Secondary Endpoint
273,NCT04980014,Type 2 Diabetes Mellitus,Change,"Total Cholesterol, Baseline","Total Cholesterol, Baseline","Baseline, Weeks 13 And 26",Secondary Endpoint
274,NCT04980014,Type 2 Diabetes Mellitus,Ldl-C),Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
275,NCT04980014,Type 2 Diabetes Mellitus,-C),Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
276,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
277,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
278,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
279,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Not Mentioned,Not Mentioned,Operative Difficulties,At The Time Of Cholecysctomy,Primary Endpoint
280,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Postoperative Complications,Not Mentioned,Not Mentioned,30 Days After The Operation,Primary Endpoint
281,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
282,NCT04979689,Erbs Palsy,Not Mentioned,Not Mentioned,Not Mentioned,12Th Weeks,Primary Endpoint
283,NCT04979689,Erbs Palsy,Not Mentioned,Not Mentioned,Not Mentioned,"12Th Weeks, 5Th Day",Secondary Endpoint
284,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
285,NCT04979481,Mental Health Wellness 1,Resilience,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
286,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
287,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
288,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
289,NCT04979364,"Chronic Pain, Opioid Misuse",Psychometric Properties,Not Mentioned,Pomi Scale,Once. At Inclusion (Test Phase),Primary Endpoint
290,NCT04979364,"Chronic Pain, Opioid Misuse",Psychometric Properties,Not Mentioned,Pomi Scale,Once. At 2 To 4 Weeks (Re-Test Phase),Primary Endpoint
291,NCT04979364,"Chronic Pain, Opioid Misuse",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
292,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Not Mentioned,Not Mentioned,Not Mentioned,At Inclusion In The Cohort During The Acute Episode,Primary Endpoint
293,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Not Mentioned,Not Mentioned,Stroke Patient,At Inclusion In The Cohort During The Acute Episode,Primary Endpoint
294,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
295,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Patient Survival,Not Mentioned,Not Mentioned,30 Days,Primary Endpoint
296,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Not Mentioned,Not Mentioned,Kidney Survival,30 Days,Primary Endpoint
297,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
298,NCT04979091,"Covid19, Critical Illness",Sex Hormone In Critical,Patients,Not Mentioned,Day At Admission,Primary Endpoint
299,NCT04979091,"Covid19, Critical Illness",Sex Hormone In Critical,Patients,Not Mentioned,Day At Admission,Primary Endpoint
300,NCT04979091,"Covid19, Critical Illness",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
301,NCT04979026,Deep Venous Thrombosis,Change Of Peak Flow Velocity,Not Mentioned,Not Mentioned,"The Peak Flow Velocity Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
302,NCT04979026,Deep Venous Thrombosis,Change Of Flow Volume,Not Mentioned,Not Mentioned,"The Flow Volume Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
303,NCT04979026,Deep Venous Thrombosis,Number Of Participants,Not Mentioned,Not Mentioned,"Stasis Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
304,NCT04979026,Deep Venous Thrombosis,Number Of Participants,Not Mentioned,Not Mentioned,"Deep Venous Thrombosis Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
305,NCT04979026,Deep Venous Thrombosis,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
306,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use","Acid (Aa) Metabolites 2,3-Dinor-Thromboxane B2 (Txm)",Not Mentioned,Leukotriene E4 (Lte4),14 Days,Primary Endpoint
307,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,7 Days,Secondary Endpoint
308,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
309,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Nicotine Equivalents,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
310,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
311,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
312,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Cotinine,14 Days,Secondary Endpoint
313,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
314,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
315,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Clearance (Nmc) Saccharin Transit Time (Stt),Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
316,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",T- And B-Lymphocytes,Not Mentioned,(Nk) Cell Profiles,14 Days,Secondary Endpoint
317,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
318,NCT04978974,"Chronic Conditions, Multiple",Perceived Stress Scale,Not Mentioned,Not Mentioned,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
319,NCT04978974,"Chronic Conditions, Multiple",Effects Of Stress Management Program,Not Mentioned,Not Mentioned,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
320,NCT04978974,"Chronic Conditions, Multiple",Effects Of Stress Management Program,Not Mentioned,Not Mentioned,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
321,NCT04978974,"Chronic Conditions, Multiple",Effects Of Stress Management Program,Baseline,Not Mentioned,Base Line Were Used In 5Th (Two Weeks And 3 Days) And 10Th Session (One Month And One Week From First Assessment),Secondary Endpoint
322,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Reported Physical Disability,Booster (12 Weeks From Baseline),Primary Endpoint
323,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Reported Physical Disability,6-Month Follow-Up,Primary Endpoint
324,NCT04978961,Chronic Pain,Ratings),Not Mentioned,Not Mentioned,6-Month Follow-Up,Primary Endpoint
325,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,"Acceptability, Fact Intervention",6-Month Follow-Up,Primary Endpoint
326,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Acceptance,Booster (12 Weeks From Baseline),Secondary Endpoint
327,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Acceptance,6-Month Follow-Up,Secondary Endpoint
328,NCT04978961,Chronic Pain,Engagement In Valued Activities,Not Mentioned,Not Mentioned,Booster (12 Weeks From Baseline),Secondary Endpoint
329,NCT04978961,Chronic Pain,Engagement In Valued Activities,Not Mentioned,Not Mentioned,6-Month Follow-Up,Secondary Endpoint
330,NCT04978883,Sjogren'S Syndrome,Not Mentioned,Not Mentioned,"Risk Factors, Pss-Ild",6 Months From Baseline,Primary Endpoint
331,NCT04978883,Sjogren'S Syndrome,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
332,NCT04978805,Cancer,Visual Analog Scale,Not Mentioned,Not Mentioned,1. Week,Primary Endpoint
333,NCT04978805,Cancer,Visual Analog Scale,Not Mentioned,Not Mentioned,4. Week,Primary Endpoint
334,NCT04978805,Cancer,Visual Analog Scale,Not Mentioned,Not Mentioned,8. Week,Primary Endpoint
335,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Pittsburgh Sleep Quality Index (Psqi),1.Week,Primary Endpoint
336,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Pittsburgh Sleep Quality Index (Psqi),4.Week,Primary Endpoint
337,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Pittsburgh Sleep Quality Index (Psqi),8.Week,Primary Endpoint
338,NCT04978805,Cancer,(Mmrc),Not Mentioned,Not Mentioned,1.Week,Primary Endpoint
339,NCT04978805,Cancer,(Mmrc),Not Mentioned,Not Mentioned,4.Week,Primary Endpoint
340,NCT04978805,Cancer,(Mmrc),Not Mentioned,Not Mentioned,8.Week,Primary Endpoint
341,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
342,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Not Mentioned,Not Mentioned,Urodynamic Stress Incontinence,November 2010 And October 2020,Primary Endpoint
343,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Detrusor Overactivity,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
344,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
345,NCT04978688,Healthy,Ee),Not Mentioned,Not Mentioned,Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
346,NCT04978688,Healthy,Not Mentioned,Not Mentioned,"(Cmax) Of Relugolix, E2",Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
347,NCT04978688,Healthy,Not Mentioned,Not Mentioned,Not Mentioned,Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
348,NCT04978688,Healthy,Change,Baseline,Not Mentioned,Week 6,Secondary Endpoint
349,NCT04978688,Healthy,(Lh),Baseline,Not Mentioned,Week 6,Secondary Endpoint
350,NCT04978688,Healthy,(P),Baseline,Not Mentioned,Week 6,Secondary Endpoint
351,NCT04978688,Healthy,Change,"And, Baseline",Not Mentioned,Week 6,Secondary Endpoint
352,NCT04978688,Healthy,And C-Telopepetide Concentrations At Week 6,Baseline,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
353,NCT04978688,Healthy,Incidence Of Treatment-Emergent Adverse Events,Not Mentioned,Not Mentioned,8 Weeks,Secondary Endpoint
354,NCT04978688,Healthy,Incidence Of Hot Flush,Not Mentioned,Not Mentioned,8 Weeks,Secondary Endpoint
355,NCT04978545,"Periapical Periodontitis, Polymerase Chain Reaction, Intracanal Medicament, Enterococcus Faecalis Infection",Sanger Sequencing,Not Mentioned,Not Mentioned,Change From Baseline To Postoperative 7 Days,Primary Endpoint
356,NCT04978545,"Periapical Periodontitis, Polymerase Chain Reaction, Intracanal Medicament, Enterococcus Faecalis Infection",S3) Taken From Teeth Were Measured Using The,Not Mentioned,Not Mentioned,Change From Baseline To Postoperative 7 Days,Primary Endpoint
357,NCT04978545,"Periapical Periodontitis, Polymerase Chain Reaction, Intracanal Medicament, Enterococcus Faecalis Infection",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
358,NCT04978532,"Procedural Pain, Pain, Acute",Venipuncture (Assessed By Children),Not Mentioned,Not Mentioned,Before Venipuncture Procedure And After Venipuncture Procedure (Immediately After The Injector Was Removed),Primary Endpoint
359,NCT04978532,"Procedural Pain, Pain, Acute",Observer),Not Mentioned,Not Mentioned,Before Venipuncture Procedure And After Venipuncture Procedure (Immediately After The Injector Was Removed),Primary Endpoint
360,NCT04978532,"Procedural Pain, Pain, Acute",Not Mentioned,Not Mentioned,Not Mentioned,"Before Venipuncture Procedure, During Venipuncture Procedure (When Needle Insertion And The First Blood Was Seen In Injector, Until Needle Removed), And After Venipuncture Procedure (Immediately After The Injector Was Removed)",Secondary Endpoint
361,NCT04978532,"Procedural Pain, Pain, Acute",Not Mentioned,Not Mentioned,Not Mentioned,"Before Venipuncture Procedure, During Venipuncture Procedure (When Needle Insertion And The First Blood Was Seen In Injector, Until Needle Removed), And After Venipuncture Procedure (Immediately After The Injector Was Removed)",Secondary Endpoint
362,NCT04978441,"Significant Correlation Between Baseline Personality Characteristics, Changing Emotions Throughout The Day, And Glycemic Levels In Patients With T1Dm",Glycemic Levels,"Patients, Correlation, Baseline, T1Dm","Patients, Correlation, Baseline, T1Dm","Through Study Completion, An Average Of 1 Year",Primary Endpoint
363,NCT04978441,"Significant Correlation Between Baseline Personality Characteristics, Changing Emotions Throughout The Day, And Glycemic Levels In Patients With T1Dm",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
364,NCT04978402,"Interchromosomal Breakpoint, Infertility",Estimate The It Carrier'S Reproductive Risk,Not Mentioned,Not Mentioned,Day 1,Primary Endpoint
365,NCT04978402,"Interchromosomal Breakpoint, Infertility",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
366,NCT04978233,Covid-19,Change,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Primary Endpoint
367,NCT04978233,Covid-19,Change,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Primary Endpoint
368,NCT04978233,Covid-19,Healthcare Team,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
369,NCT04978233,Covid-19,Change In Symptoms,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
370,NCT04978233,Covid-19,Not Mentioned,Not Mentioned,"Scheduled Teleconsultations, Patient Satisfaction",From Day 1 To Day 14,Secondary Endpoint
371,NCT04978233,Covid-19,Change In Vital Signs Temperature,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
372,NCT04978233,Covid-19,Change In Vital Signs Respiration Rate,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
373,NCT04978233,Covid-19,Change In Vital Signs Oxygen Saturation,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
374,NCT04978233,Covid-19,Change In Vital Signs Heart Rate,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
375,NCT04978233,Covid-19,Change In Vital Signs Blood Pressure,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
376,NCT04978220,"Depression Unipolar, Insomnia",Depression Scale (Hads),Not Mentioned,Not Mentioned,1 Year,Primary Endpoint
377,NCT04978220,"Depression Unipolar, Insomnia",Scale (Asds),Not Mentioned,Not Mentioned,1 Year,Secondary Endpoint
378,NCT04978155,Arterio-Venous Fistula,Time Of The Postoperative,Not Mentioned,Not Mentioned,6 Weeks,Primary Endpoint
379,NCT04978155,Arterio-Venous Fistula,Avf That Is Finally Placed,Not Mentioned,Surgical Project,During The Surgery,Secondary Endpoint
380,NCT04978155,Arterio-Venous Fistula,Our Accesses,Not Mentioned,Not Mentioned,12 Months,Secondary Endpoint
381,NCT04977921,Educational Problems,Not Mentioned,Not Mentioned,Not Mentioned,13 Lab Session-13 Weeks,Primary Endpoint
382,NCT04977921,Educational Problems,Evaluate Effectiveness,Not Mentioned,Not Mentioned,Week 14,Primary Endpoint
383,NCT04977921,Educational Problems,Assess Students' Perception,Not Mentioned,Not Mentioned,Up To 15 Weeks,Secondary Endpoint
384,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Reduce Labor Pain,Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
385,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Postpartum Comfort Levels,Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
386,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",A Maternal Information,Not Mentioned,Not Mentioned,Before Birth,Primary Endpoint
387,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Pain (Vasp),Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
388,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Ppcq),Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
389,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Evalution Labour Pain,Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
390,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Evalution Postpartum Comfort,Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
391,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
392,NCT04977687,"Machine Learning, Acute Kidney Injury, Renal Replacement Therapy, Prediction Models",Not Mentioned,"Patients, Renal Replacement Therapy","Patients, Renal Replacement Therapy",14 Days,Primary Endpoint
393,NCT04977687,"Machine Learning, Acute Kidney Injury, Renal Replacement Therapy, Prediction Models",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
394,NCT04977661,Nonalcoholic Steatohepatitis (Nash),Resolution Of Nash,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
395,NCT04977661,Nonalcoholic Steatohepatitis (Nash),Ast),Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
396,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Tumor Size,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
397,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Tumor Location,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
398,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Number Of Lesions,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
399,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
400,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Tumor Texture,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
401,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Tail Contraction,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
402,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
403,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Pancreatic Duct/Bile Duct Dilatation,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
404,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
405,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
406,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
407,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,"Pancreas Plain Scan, Ct Value",Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
408,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Plain Scan,Not Mentioned,Ct Value,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
409,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,"Pancreas Artery Phase, Ct Value",Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
410,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,"Of Lesion Artery Phase, Ct Value",Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
411,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,"Pancreas Portal Phase, Ct Value",Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
412,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Ct Value,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
413,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
414,NCT04977557,Dry Beriberi,Change In Overall Neuropathy Limitation Scale (Onls) Score,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Primary Endpoint
415,NCT04977557,Dry Beriberi,Change In Leg Swelling,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
416,NCT04977557,Dry Beriberi,Change In Muscle Power,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
417,NCT04977557,Dry Beriberi,Change In Muscle Cramp,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
418,NCT04977557,Dry Beriberi,Change In Deep Tendon Reflexes,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
419,NCT04977557,Dry Beriberi,Change In Squat Test,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
420,NCT04977557,Dry Beriberi,Change In Pain Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
421,NCT04977557,Dry Beriberi,Change In Position Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
422,NCT04977557,Dry Beriberi,Change In Vibration Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
423,NCT04977557,Dry Beriberi,Change In Touch Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
424,NCT04977518,Infective Endocarditis,Heart Failure) Of Infective Endocarditis,Not Mentioned,Not Mentioned,"During The Hospitalization, Average Of 1 Months",Primary Endpoint
425,NCT04977518,Infective Endocarditis,Not Mentioned,Not Mentioned,Not Mentioned,"During The Hospitalization, Average Of 1 Months",Primary Endpoint
426,NCT04977518,Infective Endocarditis,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
427,NCT04977505,Shoulder Dislocation,Hounsfield Unit Of Anchor Tunnel,Not Mentioned,Not Mentioned,2 Years After Surgery,Primary Endpoint
428,NCT04977505,Shoulder Dislocation,The Diameter Of Anchor Tunnel,Not Mentioned,Not Mentioned,2 Years After Surgery,Primary Endpoint
429,NCT04977505,Shoulder Dislocation,Not Mentioned,Not Mentioned,Hounsfield Unit Of Ossification Site,2 Years After Surgery,Primary Endpoint
430,NCT04977505,Shoulder Dislocation,Unossified Area Of Anchor Tunnel,Not Mentioned,Not Mentioned,2 Years After Surgery,Secondary Endpoint
431,NCT04977505,Shoulder Dislocation,Ossification Quality Score,Not Mentioned,Not Mentioned,2 Years After Surgery,Secondary Endpoint
432,NCT04977440,Intensive Care Unit Syndrome,Glycemic Control,Effect,Not Mentioned,Up To 7 Days,Primary Endpoint
433,NCT04977440,Intensive Care Unit Syndrome,Serum Electrolytes,Effect,Not Mentioned,Up To 7 Days,Primary Endpoint
434,NCT04977440,Intensive Care Unit Syndrome,High Protein Intake,"Effect, Icu Outcome","Effect, Icu Outcome",Up To 7 Days,Secondary Endpoint
435,NCT04977219,Stroke,Not Mentioned,Scale,Not Mentioned,Up To 55 Days,Primary Endpoint
436,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
437,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
438,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Discharge Destination,Up To 55 Days,Secondary Endpoint
439,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Analog Scale.,Not Mentioned,Not Mentioned,3Day,Primary Endpoint
440,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Not Mentioned,Not Mentioned,Not Mentioned,3 Day,Secondary Endpoint
441,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Richards-Campbell Sleep Scale,Not Mentioned,Not Mentioned,3 Day,Secondary Endpoint
442,NCT04976673,"Lichen Planus, Oral",Size Of Oral Lichen Planus,Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
443,NCT04976673,"Lichen Planus, Oral",Not Mentioned,Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
444,NCT04976543,"Cirrhosis, Portal Vein Thrombosis, Esophageal Varices",Rebleeding,Not Mentioned,Not Mentioned,6-Week,Primary Endpoint
445,NCT04976543,"Cirrhosis, Portal Vein Thrombosis, Esophageal Varices",Death,Not Mentioned,Not Mentioned,6-Week,Secondary Endpoint
446,NCT04976504,"Desaturation Of Blood, Anesthesia",Not Mentioned,Not Mentioned,Additional Warning Time Provided,"From Time Of Starting Preoxygenation Until The Time Of Spo2 90%, Assessed Up To 20 Minutes",Primary Endpoint
447,NCT04976504,"Desaturation Of Blood, Anesthesia",Not Mentioned,Correlation,Not Mentioned,Ori And Pao2,Secondary Endpoint
448,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,Not Mentioned,Not Mentioned,January 2017 - June 2021,Primary Endpoint
449,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,Not Mentioned,Tumor Nature,January 2017 - June 2021,Primary Endpoint
450,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,Not Mentioned,Not Mentioned,January 2017 - June 2021,Primary Endpoint
451,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
452,NCT04976361,Prp,Not Mentioned,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
453,NCT04976361,Prp,Not Mentioned,Not Mentioned,Retinal Thickness,6 Months,Primary Endpoint
454,NCT04976361,Prp,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
455,NCT04976114,Anxiety,Anxiety Level,Not Mentioned,Not Mentioned,"Presurgery, Just The Moment Before To Surgery",Primary Endpoint
456,NCT04976114,Anxiety,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
457,NCT04976088,"Trauma Injury, Inflammation","100"")","Baseline, Pain","Baseline, Pain",72 ± 2 Hours (Day 4) After Treatment Start.,Primary Endpoint
458,NCT04976088,"Trauma Injury, Inflammation",Day 8 (Spid0-4D,Not Mentioned,"Spid0-8D), Pain",Day 4 And Day 8,Secondary Endpoint
459,NCT04976088,"Trauma Injury, Inflammation","100"")","Time-Points (Including Patients' Home Measurements), From Day 1 To Day 8., Baseline, Pain","Time-Points (Including Patients' Home Measurements), From Day 1 To Day 8., Baseline, Pain","Day 1, Day 2, Day 3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
460,NCT04976088,"Trauma Injury, Inflammation","100"") During","Time To Resolution Of Pain, Baseline, Day 8","Time To Resolution Of Pain, Baseline, Day 8",From Day 1 Until The Date Of Resolution Of Pain At Rest (Maximum Day 8),Secondary Endpoint
461,NCT04976088,"Trauma Injury, Inflammation","100"")","Treatment Start, Baseline","Treatment Start, Baseline",Day 4 And Day 8,Secondary Endpoint
462,NCT04976088,"Trauma Injury, Inflammation","100"")","Movement), Baseline, Pain","Movement), Baseline, Pain",72 ± 2 Hours (Day 4) After Treatment Start,Secondary Endpoint
463,NCT04976088,"Trauma Injury, Inflammation",Patient Diary,"Rescue Medication (Paracetamol), Baseline, Day 8","Rescue Medication (Paracetamol), Baseline, Day 8",From Baseline To Day 8,Secondary Endpoint
464,NCT04976088,"Trauma Injury, Inflammation",Patient Diary,"Baseline, Day 8",Not Mentioned,From Baseline To Day 8,Secondary Endpoint
465,NCT04976088,"Trauma Injury, Inflammation",75% Adhered; 3:<50% Adhered But Not Detached,"Patients, Ordinal Scale: 0:≥90","Patients, Ordinal Scale: 0:≥90","Day 1, Day 2, Day 3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
466,NCT04976088,"Trauma Injury, Inflammation",Physical Examination Using Observation,"Auscultation, Baseline, Day 8","Auscultation, Baseline, Day 8","Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
467,NCT04976088,"Trauma Injury, Inflammation",Safety As Change,"Blood Pressure Measured In Mmhg, Baseline, Day 8","Blood Pressure Measured In Mmhg, Baseline, Day 8","Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
468,NCT04976088,"Trauma Injury, Inflammation",Safety As Change,"Blood Pressure Measured In Mmhg, Baseline, Day 8","Blood Pressure Measured In Mmhg, Baseline, Day 8","Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
469,NCT04976088,"Trauma Injury, Inflammation",Heart Rate Measured In Bpm,"Baseline, Day 8",Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
470,NCT04976088,"Trauma Injury, Inflammation",Number Of Patient,"Baseline, Day 8",Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
471,NCT04976088,"Trauma Injury, Inflammation",Number Of Adverse Events,"Baseline, Day 8",Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
472,NCT04976088,"Trauma Injury, Inflammation",8 Based,"Day, Local Tolerability (Erythema), Beyond Test Site, Site","Day, Local Tolerability (Erythema), Beyond Test Site, Site","Day 1, Day 4 And Day 8",Secondary Endpoint
473,NCT04976088,"Trauma Injury, Inflammation",8 Based,"Day, Site, Local Tolerability (Itching)","Day, Site, Local Tolerability (Itching)",4-Point,Secondary Endpoint
474,NCT04976088,"Trauma Injury, Inflammation",8 Based,"Day, Local Tolerability (Burning), Site","Day, Local Tolerability (Burning), Site",4-Point,Secondary Endpoint
475,NCT04976088,"Trauma Injury, Inflammation",8 Based,"Day, Local Tolerability (Local Pain), Site","Day, Local Tolerability (Local Pain), Site",4-Point,Secondary Endpoint
476,NCT04976088,"Trauma Injury, Inflammation",Day 4,Not Mentioned,"Day 8., Following Score: 3, Local Tolerability, Administration Site",Day 4 And Day 8,Secondary Endpoint
477,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Mean Change In Pain Score,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Primary Endpoint
478,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Flare) Scores,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Primary Endpoint
479,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Resolution Of Pain,Not Mentioned,Not Mentioned,Assessed For 1 Months After Drug Insertion,Secondary Endpoint
480,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Resolution Of Anterior Chamber Inflammation,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
481,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Not Mentioned,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
482,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Number Of Patient,Not Mentioned,Call-Backs Regarding Post-Operative Pain,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
483,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Number Of Pharmacy Call-Backs Regarding Post-Operative Medication,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
484,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Not Mentioned,Not Mentioned,Adverse Events,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
485,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Mean Change In Iop,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
486,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Change In Bcva,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
487,NCT04975659,Communication,Pain Score,Not Mentioned,Not Mentioned,"Throughout Study Completion, Average Of 10 Months",Primary Endpoint
488,NCT04975659,Communication,Anxiety Score,Baseline,Not Mentioned,"Through Study Completion, Average Of 10 Months",Primary Endpoint
489,NCT04975659,Communication,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Primary Endpoint
490,NCT04975659,Communication,Anxiety Score,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Secondary Endpoint
491,NCT04975659,Communication,Anxiety Score,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Secondary Endpoint
492,NCT04975542,Respiratory Function Impaired,Change In Chest Wall Excursion,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Chest Wall Excursion Within 5 Minutes Of Treatment Completion.,Primary Endpoint
493,NCT04975542,Respiratory Function Impaired,Change In Forced Vital Capacity (Fvc),Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Fvc Value Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
494,NCT04975542,Respiratory Function Impaired,1 Second (Fev1),Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline In Forced Expiratory Volume At 1 Second Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
495,NCT04975542,Respiratory Function Impaired,Fev1/Fvc Ratio,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Fev1/Fvc Ratio Value Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
496,NCT04975542,Respiratory Function Impaired,Change In Respiratory Rate,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Respiratory Rate Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
497,NCT04975542,Respiratory Function Impaired,Change In Heart Rate,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Heart Rate Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
498,NCT04975542,Respiratory Function Impaired,Not Mentioned,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Oxygen Saturation Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
499,NCT04975529,"Exercise, Diet",Patient-Reported Outcomes Measurement Information System (Promis,Baseline,Not Mentioned,6-Months,Primary Endpoint
500,NCT04975529,"Exercise, Diet",Mean Change,Baseline,Not Mentioned,6-Months,Secondary Endpoint
501,NCT04975529,"Exercise, Diet",Institute (Nci) Fruit,"Vegetable Screener, Baseline","Vegetable Screener, Baseline",6-Months,Secondary Endpoint
502,NCT04975529,"Exercise, Diet",Confidence Scale,Baseline,Not Mentioned,6-Months,Secondary Endpoint
503,NCT04975412,Acne Vulgaris,Not Mentioned,Not Mentioned,Acne Severity,Initial Consult,Primary Endpoint
504,NCT04975412,Acne Vulgaris,Whole Blood Zinc Level,Not Mentioned,Not Mentioned,Initial Consult,Primary Endpoint
505,NCT04975412,Acne Vulgaris,Not Mentioned,Demographics,Not Mentioned,Initial Consult,Secondary Endpoint
506,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,At 07:00 Hours After Caffeine And Placebo Administration,Primary Endpoint
507,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Recording Of Nocturnal Sleep,Between 03:00-07:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
508,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Caffeine Effects Questionnaire,Between 07:15-08:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
509,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Negative Affect Schedule,Not Mentioned,Not Mentioned,Between 07:00-08:15 Hours After Caffeine And Placebo Administration,Secondary Endpoint
510,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Psychomotor Vigilance Task,Not Mentioned,Not Mentioned,Between 07:15-07:30 Hours After Caffeine And Placebo Administration,Secondary Endpoint
511,NCT04975360,"Sleep Inertia, Caffeine, Placebo",N-Back Task,Not Mentioned,Not Mentioned,Between 07:30-07:40 Hours After Caffeine And Placebo Administration,Secondary Endpoint
512,NCT04975360,"Sleep Inertia, Caffeine, Placebo",D2 Attention Task,Not Mentioned,Not Mentioned,Between 07:40-07:45 Hours After Caffeine And Placebo Administration,Secondary Endpoint
513,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,Between 07:00-08:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
514,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Recording Of Morning Nap Opportunity,Between 08:00-09:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
515,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
516,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
517,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Proximal Contact,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
518,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Marginal Adaptation,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
519,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
520,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Gingival Status,24 Months,Primary Endpoint
521,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",The Crown,Not Mentioned,Retention,24 Months,Primary Endpoint
522,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",The Veneer/Composite,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
523,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
524,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",History Of Trauma,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
525,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Clinical Pulp Pathology,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
526,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Radiographical Pulp Pathology,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
527,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Parent'S Esthetic Satisfaction,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
528,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
529,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Transition To,Not Mentioned,Not Mentioned,"From Transition To Breastfeeding, Up To 1 Week.",Primary Endpoint
530,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Not Mentioned,Not Mentioned,Not Mentioned,"From Admission To Discharge, Up To 4 Weeks",Primary Endpoint
531,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
532,NCT04975126,Cataract,Decisional Conflict Scale Score,Not Mentioned,Not Mentioned,Day Of Pre-Assessment Visit (1 Week Before Surgery),Primary Endpoint
533,NCT04975126,Cataract,Decision Regret Scale Score,Not Mentioned,Not Mentioned,1 Month After Surgery,Primary Endpoint
534,NCT04975126,Cataract,Number Of Correctly Answered Questions Assessing Knowledge,Not Mentioned,Not Mentioned,Day Of Pre-Assessment Visit (1 Week Before Surgery),Primary Endpoint
535,NCT04975126,Cataract,Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
536,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Scale Score,Not Mentioned,And 12Th. Weeks,"Before And After Treatment (12 Sessions, 6Th. And 12Th. Weeks)]",Primary Endpoint
537,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Change From Isokinetic Muscle Strength,Not Mentioned,"And 12Th. Weeks, Femoris Muscles","Before And After Treatment (12 Sessions, 6Th. And 12Th. Weeks)]",Primary Endpoint
538,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
539,NCT04975048,"Healthy, Gen1 Gene Mutation",Changes In Serum Lipids,Not Mentioned,Not Mentioned,"Week 0, Week 4, Week 8, Week 16",Primary Endpoint
540,NCT04975048,"Healthy, Gen1 Gene Mutation",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
541,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Primary Endpoint
542,NCT04975022,"Pk, Pd, And Safety",Auc 0-8 H,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Primary Endpoint
543,NCT04975022,"Pk, Pd, And Safety","Aucgir,0-8 H",Not Mentioned,Not Mentioned,"Pre-Dose, 0-8 Hours",Primary Endpoint
544,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 0-8 Hours",Primary Endpoint
545,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300,330,360,420,480 Minutes；",Secondary Endpoint
546,NCT04975022,"Pk, Pd, And Safety",Auc 0-2 H,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120 Minutes",Secondary Endpoint
547,NCT04975022,"Pk, Pd, And Safety",The Elimination Half-Life (T1/2) Of Serum Insulin,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Secondary Endpoint
548,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,"Time Zero To 4 H, Insulin","Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240 Minutes",Secondary Endpoint
549,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,"Time Zero To Infinite Time, Insulin","Pre-Dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Secondary Endpoint
550,NCT04975022,"Pk, Pd, And Safety",Aucgir，0-2 H,Not Mentioned,Not Mentioned,"Pre-Dose, 0-2 Hours",Secondary Endpoint
551,NCT04975022,"Pk, Pd, And Safety",Aucgir，0-4 H,Not Mentioned,Not Mentioned,"Pre-Dose, 0-4 Hours",Secondary Endpoint
552,NCT04975022,"Pk, Pd, And Safety",Tgirmax,Not Mentioned,Not Mentioned,"Pre-Dose, 0-8 Hours",Secondary Endpoint
553,NCT04974983,"Glioblastoma, Angiogenesis",Not Mentioned,Not Mentioned,Not Mentioned,15 Months,Primary Endpoint
554,NCT04974983,"Glioblastoma, Angiogenesis",Not Mentioned,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
